Michel Lagarde was named President and Chief Executive Officer of West Pharmaceutical Services Inc, succeeding Eric M. Green. As of November 6, 2026, West Pharmaceutical Services Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 1, 2026, naming 1 appointment and 2 departures (Form 8-K, June 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like West Pharmaceutical Services Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Eric M. Green · Role: Chief Executive Officer · 8-K, 2026-06-01
- · In / out: Out · Person: Eric M. Green · Role: Director · 8-K, 2026-06-01
- · In / out: In · Person: Michel Lagarde · Role: President and Chief Executive Officer · 8-K, 2026-06-01
West Pharmaceutical Services Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-01. It names 2 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as West Pharmaceutical Services Inc files it.
Also on the record for West Pharmaceutical Services Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.5% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 5% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.48% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.69% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| October 31, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 13.49% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs West Pharmaceutical Services Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on West Pharmaceutical Services Inc and the records around it.
West Pharmaceutical Services Inc elsewhere on the record
Companies that share a holder
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch West Pharmaceutical Services Inc
Get an email when West Pharmaceutical Services Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on West Pharmaceutical Services Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on West Pharmaceutical Services Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on West Pharmaceutical Services Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-01 | Out | Chief Executive Officer | 8-K, 2026-06-01 | ||
| 2026-06-01 | Out | Director | 8-K, 2026-06-01 | ||
| 2026-06-01 | In | President and Chief Executive Officer | 8-K, 2026-06-01 |
Who leads West Pharmaceutical Services Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President and Chief Executive Officer: Michel Lagarde, appointed (filed 2026-06-01).
- Director: Eric M. Green, departure reported (filed 2026-06-01). No successor is named in these filings.
- Chief Executive Officer: Eric M. Green, departure reported (filed 2026-06-01). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on West Pharmaceutical Services Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at West Pharmaceutical Services Inc, with the record behind each one.
Find candidates like Chief Executive Officer at West Pharmaceutical Services IncEvery change, in the filing's words
Departing: Eric M. Green, Chief Executive Officer
On March 9, 2026, West Pharmaceutical Services, Inc. (the "Company") filed a Current Report on Form 8-K announcing that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the "Board") of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition.
Departing: Eric M. Green, Director
As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.
Appointed: Michel Lagarde, President and Chief Executive Officer
Pursuant to the Employment Agreement, Mr. Lagarde will serve as President and Chief Executive Officer of the Company, will be appointed as a member of the Board as of the Start Date, and will be recommended for election as a member of the Board at future shareholder meetings as long as he is President and Chief Executive Officer.
- On June 1, 2026, the Company announced the appointment of Michel Lagarde as President and Chief Executive Officer of the Company, effective August 31, 2026 (the "Start Date"), to replace Mr. Green in those roles.
- As of the Start Date, Lead Independent Director Robert F. Friel will become Chair of the Board.
- Mr. Lagarde, 52, has served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, Inc., with responsibility for the majority of the company's businesses.
- He joined Thermo Fisher in 2017 as Senior Vice President and President, Pharma Services, through its acquisition of Patheon N.V. Before Thermo Fisher, Mr. Lagarde was President and Chief Operating Officer at Patheon N.V., a pharma services company, from 2016 to 2017, and Managing Director at JLL Partners, a private equity firm focused on health care services, from 2008 to 2016.
- Earlier in his career, he spent 12 years at Philips, a global leader in health technology, in a range of finance roles across several international markets.
- In 2023, Mr. Lagarde joined the Board of Directors of Vertex Pharmaceuticals, where he serves as Chair of the Audit and Finance Committee.
- He holds a Bachelor of Business Administration (BBA) from European University in Antwerp, Belgium, and an executive master's degree in finance and control from Maastricht University in the Netherlands.
Tools for this story
Each opens in a new tab, filled in for West Pharmaceutical Services Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.